dc.contributor.author | Vaidya, A | |
dc.contributor.author | Borgonovi, E | |
dc.contributor.author | Taylor, RS | |
dc.contributor.author | Sahel, J-A | |
dc.contributor.author | Rizzo, S | |
dc.contributor.author | Stanga, PE | |
dc.contributor.author | Kukreja, A | |
dc.contributor.author | Walter, P | |
dc.date.accessioned | 2018-02-26T09:22:12Z | |
dc.date.issued | 2014-04-14 | |
dc.description.abstract | BACKGROUND: Retinitis Pigmentosa (RP) is a hereditary genetic disease causing bilateral retinal degeneration. RP is a leading cause of blindness resulting in incurable visual impairment and drastic reduction in the Quality of life of the patients. Second Sight Medical Products Inc. developed Argus II, a retinal prosthesis system for treating RP. Argus II is the world's first ever-commercial implant intended to restore some vision in the blind patients. The objective of this study was to assess the cost-effectiveness of the Argus® II Retinal Prosthesis System (Argus II) in Retinitis Pigmentosa (RP) patients. METHOD: A multi -state transition Markov model was developed to determine the cost-effectiveness of Argus II versus usual care in RP from the perspective of healthcare payer. A hypothetical cohort of 1000 RP patients aged 46 years followed up over a (lifetime) 25-year time horizon. Health outcomes were expressed as quality adjusted life years (QALYs) and direct healthcare costs expressed in 2012 €. Results are reported as incremental cost per ratios (ICERs) with outcomes and costs discounted at an annual rate of 3.5%. RESULTS: The ICER for Argus II was €14,603/QALY. Taking into account the uncertainty in model inputs the ICER was €14,482/QALY in the probabilistic analysis. In the scenarios of an assumption of no reduction on cost across model visual acuity states or a model time horizon as short as 10 years the ICER increased to €31,890/QALY and €49,769/QALY respectively. CONCLUSION: This economic evaluation shows that Argus II is a cost-effective intervention compared to usual care of the RP patients. The lifetime analysis ICER for Argus II falls below the published societal willingness to pay of EuroZone countries. | en_GB |
dc.identifier.citation | Vol. 14: 49 | en_GB |
dc.identifier.doi | 10.1186/1471-2415-14-49 | |
dc.identifier.uri | http://hdl.handle.net/10871/31664 | |
dc.language.iso | en | en_GB |
dc.publisher | BioMed Central | en_GB |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/24731533 | en_GB |
dc.rights | © 2014 Vaidya et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated. | en_GB |
dc.subject | Cost-Benefit Analysis | en_GB |
dc.subject | Female | en_GB |
dc.subject | Follow-Up Studies | en_GB |
dc.subject | Health Care Costs | en_GB |
dc.subject | Humans | en_GB |
dc.subject | Markov Chains | en_GB |
dc.subject | Middle Aged | en_GB |
dc.subject | Models, Statistical | en_GB |
dc.subject | Prostheses and Implants | en_GB |
dc.subject | Quality-Adjusted Life Years | en_GB |
dc.subject | Retinitis Pigmentosa | en_GB |
dc.title | The cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2018-02-26T09:22:12Z | |
dc.identifier.issn | 1471-2415 | |
exeter.place-of-publication | England | en_GB |
dc.description | This is the final version of the article. Available from the publisher via the DOI in this record. | en_GB |
dc.identifier.journal | BMC Ophthalmology | en_GB |